NZ595432A - 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 - Google Patents

4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

Info

Publication number: NZ595432A
Authority: NZ; New Zealand
Prior art keywords: phenyl; compound; ccr2; azetidinyl; ylcarbamoyl
Prior art date: 2009-04-17

Application number

NZ595432A

Other languages

English (en)

Inventor

Heather Rae Hufnagel

Zhihua Sui

Xuqing Zhang

Cuifen Hou

Dana L Johnson

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-17

Filing date

2010-04-15

Publication date

2013-12-20

2010-04-15 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2013-12-20 Publication of NZ595432A publication Critical patent/NZ595432A/en

Links

VOBLMJKUYJTNEK-UHFFFAOYSA-N 1-(4-phenylcyclohexyl)azetidine Chemical compound C1CCN1C1CCC(C=2C=CC=CC=2)CC1 VOBLMJKUYJTNEK-UHFFFAOYSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 1
101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
BMLROKUGLNDMRR-UHFFFAOYSA-N n-[2-[[1-[4-(3-aminophenyl)-4-hydroxycyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound NC1=CC=CC(C2(O)CCC(CC2)N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)=C1 BMLROKUGLNDMRR-UHFFFAOYSA-N 0.000 abstract 1
LYTSOOZQXOHDBG-UHFFFAOYSA-N n-[2-[[1-[4-(3-cyanophenyl)-4-hydroxycyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound C1CC(O)(C=2C=C(C=CC=2)C#N)CCC1N(C1)CC1NC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 LYTSOOZQXOHDBG-UHFFFAOYSA-N 0.000 abstract 1
XUXGRGHZAIOCSD-UHFFFAOYSA-N n-[2-[[1-[4-amino-4-(3-methoxyphenyl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound COC1=CC=CC(C2(N)CCC(CC2)N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)=C1 XUXGRGHZAIOCSD-UHFFFAOYSA-N 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Oncology (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

NZ595432A 2009-04-17 2010-04-15 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 NZ595432A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17030709P	2009-04-17	2009-04-17
PCT/US2010/031265 WO2010121046A1 (en)	2009-04-17	2010-04-15	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

Publications (1)

Publication Number	Publication Date
NZ595432A true NZ595432A (en)	2013-12-20

Family

ID=42167720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ595432A NZ595432A (en)	2009-04-17	2010-04-15	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

Country Status (14)

Country	Link
US (2)	US20100267689A1 (2)
EP (1)	EP2419419B1 (2)
JP (1)	JP5675773B2 (2)
KR (1)	KR20120006544A (2)
CN (1)	CN102459227B (2)
AR (1)	AR076328A1 (2)
AU (1)	AU2010236346B2 (2)
BR (1)	BRPI1016189A2 (2)
CA (1)	CA2758934A1 (2)
ES (1)	ES2528625T3 (2)
MX (1)	MX2011010964A (2)
NZ (1)	NZ595432A (2)
TW (1)	TW201102377A (2)
WO (1)	WO2010121046A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2011006226A (es)	2008-12-10	2011-06-24	Janssen Pharmaceutica Nv	Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol del receptor 2 de citocina quimioatrayente.
TW201105649A (en) *	2009-04-16	2011-02-16	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
CN102459226B (zh)	2009-04-17	2014-09-17	詹森药业有限公司	Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
EP2419419B1 (en)	2009-04-17	2014-12-03	Janssen Pharmaceutica NV	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
TW201211027A (en) *	2010-06-09	2012-03-16	Janssen Pharmaceutica Nv	Cyclohexyl-azetidinyl antagonists of CCR2
US8518969B2 (en)	2010-06-17	2013-08-27	Janssen Pharmaceutica Nv	Cyclohexyl-azetidinyl antagonists of CCR2
US20140329809A1 (en)	2011-10-28	2014-11-06	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
EP2780015B1 (en)	2011-11-18	2017-01-04	Heptares Therapeutics Limited	Muscarinic m1 receptor agonists
DK2785710T3 (en) *	2011-12-01	2017-12-04	Chemocentryx Inc	SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS
JP5977349B2 (ja)	2012-06-15	2016-08-24	田辺三菱製薬株式会社	芳香族複素環化合物
GB201404922D0 (en)	2014-03-19	2014-04-30	Heptares Therapeutics Ltd	Pharmaceutical compounds
DK3209655T3 (da)	2014-10-24	2020-09-28	Landos Biopharma Inc	Lanthioninsyntease C-lignende 2-baserede Therapeutica
ES2764840T3 (es)	2015-01-28	2020-06-04	Univ Bordeaux	Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
DK3297438T3 (da)	2015-05-21	2022-01-17	Chemocentryx Inc	Ccr2-modulatorer
GB201513743D0 (en)	2015-08-03	2015-09-16	Heptares Therapeutics Ltd	Muscarinic agonists
GB201519352D0 (en)	2015-11-02	2015-12-16	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201617454D0 (en)	2016-10-14	2016-11-30	Heptares Therapeutics Limited	Pharmaceutical compounds
US10259787B2 (en)	2016-10-14	2019-04-16	Heptares Therapeutics Limited	Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
CA3293051A1 (en)	2017-09-25	2026-03-02	Chemocentryx, Inc.	Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
KR20200090873A (ko)	2017-11-30	2020-07-29	란도스 바이오파마, 인크.	란티오닌 c-유사 단백질 2 리간드 및 이와 함께 제조된 세포를 이용한 치료법
CN112105353B (zh)	2018-01-08	2024-04-19	凯莫森特里克斯股份有限公司	Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
GB201810239D0 (en)	2018-06-22	2018-08-08	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819960D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819961D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB202020191D0 (en)	2020-12-18	2021-02-03	Heptares Therapeutics Ltd	Pharmaceutical compounds
CN110028395A (zh) *	2019-05-29	2019-07-19	宁夏中星显示材料有限公司	一种4-(4-羟基苯基)环己酮的制备方法
KR20230026522A (ko)	2019-12-20	2023-02-24	란도스 바이오파마, 인크.	란티오닌 c-유사 단백질 2 리간드, 이로 제조된 세포, 및 이를 사용하는 치료법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002505684A (ja)	1997-06-18	2002-02-19	メルクエンドカンパニーインコーポレーテッド	α１ａアドレナリン受容体拮抗薬
US6037354A (en) *	1997-06-18	2000-03-14	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
AU4796700A (en) *	1999-05-13	2000-12-05	Dupont Pharmaceuticals Research Laboratories, Inc.	Ureido-substituted cyclic amine derivatives and their use as drug
CA2378499A1 (en)	1999-08-04	2001-02-15	Teijin Limited	Cyclic amine ccr3 antagonists
US6245799B1 (en) *	1999-11-08	2001-06-12	American Home Products Corp	[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
JP2003513970A (ja)	1999-11-08	2003-04-15	ワイス	中枢神経系障害の治療のための［（インドール−３−イル）−シクロアルキル］−３−置換アゼチジン
US6706712B2 (en) *	2000-12-20	2004-03-16	Bristol-Myers Squibb Pharma Company	Cyclic derivatives as modulators of chemokine receptor activity
EP1377625B1 (de) *	2001-03-26	2006-06-14	Bayer MaterialScience AG	Polycarbonat mit ausgeprägtem scherentzähungsverhalten
EP1565436B1 (en) *	2002-11-27	2012-04-25	Incyte Corporation	3-aminopyrrolidine derivatives as modulators of chemokine receptors
CN1741994A (zh) *	2002-11-27	2006-03-01	因塞特公司	作为趋化因子受体调节剂的3－氨基吡咯烷衍生物
KR20080052683A (ko)	2003-12-18	2008-06-11	인사이트 코포레이션	케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
CN101065374A (zh) *	2004-09-28	2007-10-31	詹森药业有限公司	取代的二哌啶化学引诱物细胞因子受体2拮抗剂
PA8653301A1 (es) *	2004-11-22	2006-11-09	Incyte Corp Incyte Corp	Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
GB0513747D0 (en)	2005-07-06	2005-08-10	Merck Sharp & Dohme	Therapeutic compounds
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
WO2007130712A1 (en)	2006-01-31	2007-11-15	Janssen Pharmaceutica, Nv	Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
AR063275A1 (es) *	2006-10-12	2009-01-14	Epix Delaware Inc	Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
BRPI0820701A2 (pt) *	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
MX2011006226A (es) *	2008-12-10	2011-06-24	Janssen Pharmaceutica Nv	Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol del receptor 2 de citocina quimioatrayente.
TW201105649A (en) *	2009-04-16	2011-02-16	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
CN102459226B (zh) *	2009-04-17	2014-09-17	詹森药业有限公司	Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
EP2419419B1 (en)	2009-04-17	2014-12-03	Janssen Pharmaceutica NV	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

2010
- 2010-04-15 EP EP10714804.1A patent/EP2419419B1/en active Active
- 2010-04-15 KR KR1020117026846A patent/KR20120006544A/ko not_active Withdrawn
- 2010-04-15 ES ES10714804.1T patent/ES2528625T3/es active Active
- 2010-04-15 CN CN201080027641.6A patent/CN102459227B/zh not_active Expired - Fee Related
- 2010-04-15 NZ NZ595432A patent/NZ595432A/en not_active IP Right Cessation
- 2010-04-15 US US12/761,080 patent/US20100267689A1/en not_active Abandoned
- 2010-04-15 MX MX2011010964A patent/MX2011010964A/es active IP Right Grant
- 2010-04-15 AU AU2010236346A patent/AU2010236346B2/en not_active Ceased
- 2010-04-15 JP JP2012506232A patent/JP5675773B2/ja not_active Expired - Fee Related
- 2010-04-15 WO PCT/US2010/031265 patent/WO2010121046A1/en not_active Ceased
- 2010-04-15 CA CA2758934A patent/CA2758934A1/en not_active Abandoned
- 2010-04-15 BR BRPI1016189A patent/BRPI1016189A2/pt not_active Application Discontinuation
- 2010-04-16 TW TW099111898A patent/TW201102377A/zh unknown
- 2010-04-19 AR ARP100101287A patent/AR076328A1/es unknown
2011
- 2011-10-25 US US13/280,690 patent/US8513229B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2758934A1 (en)	2010-10-21
US20120040960A1 (en)	2012-02-16
US8513229B2 (en)	2013-08-20
TW201102377A (en)	2011-01-16
EP2419419A1 (en)	2012-02-22
MX2011010964A (es)	2011-11-02
JP2012524111A (ja)	2012-10-11
CN102459227B (zh)	2014-08-20
CN102459227A (zh)	2012-05-16
AR076328A1 (es)	2011-06-01
EP2419419B1 (en)	2014-12-03
JP5675773B2 (ja)	2015-02-25
BRPI1016189A2 (pt)	2016-04-19
KR20120006544A (ko)	2012-01-18
WO2010121046A1 (en)	2010-10-21
US20100267689A1 (en)	2010-10-21
AU2010236346A1 (en)	2011-11-03
ES2528625T3 (es)	2015-02-11
AU2010236346B2 (en)	2015-01-22

Legal Events

Date	Code	Title	Description
2014-03-28	PSEA	Patent sealed
2014-06-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2017 BY CPA GLOBAL Effective date: 20140602
2014-09-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2020 BY CPA GLOBAL Effective date: 20140906
2020-10-30	LAPS	Patent lapsed

Publication	Publication Date	Title
NZ595432A (en)	2013-12-20	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
NZ593004A (en)	2013-05-31	Azaazulene compounds
GEP20156216B (en)	2015-01-12	Heterocyclic compound and usage thereof
NZ596538A (en)	2014-04-30	Haloalkyl heteroaryl benzamide compounds
NZ599513A (en)	2013-11-29	Compounds for the treatment of dyslipidemia and related diseases
UA102251C2 (ru)	2013-06-25	Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
GEP20156309B (en)	2015-07-10	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ596826A (en)	2014-03-28	Polycyclic antagonists of lysophosphatidic acid receptors
NO20080897L (no)	2008-02-20	Salter av 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
ATE557024T1 (de)	2012-05-15	Piperidinverbindungen als gpcr-agonisten
ATE537168T1 (de)	2011-12-15	Substituierte oxazolidinone und ihre verwendung
GEP20156319B (en)	2015-07-10	Asymmetric ureas and medical uses thereof
MX2010008397A (es)	2010-08-23	Inhibidores del receptor de quimioquinas cxcr3.
ATE557023T1 (de)	2012-05-15	Piperidinylverbindungen als gpcr-agonisten
BR112012013733A2 (pt)	2016-03-22	composição de cuidado pessoal, fornecendo intensificação de silêncio e maciez e artigos usando a mesma
MA32544B1 (fr)	2011-08-01	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
PT2139334E (pt)	2013-10-02	Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
UA102432C2 (ru)	2013-07-10	Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MX2010007588A (es)	2010-08-06	Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor de esfingosina-1-fosfato (s1p).
MY186456A (en)	2021-07-22	Quinazoline carboxamide azetidines
ATE538100T1 (de)	2012-01-15	Aminotetrahydroindazoloessigsäuren
GEP20135913B (en)	2013-08-26	1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
ITMI20091618A1 (it)	2010-04-01	Pezzo composito, nonche' impiego del pezzo composito
PE20091431A1 (es)	2009-10-19	Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica